// App-Quantinova.ai

SA-OR40 : Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with CKD, Diabetes, and Recent Acute Coronary Syndrome: Results from the BETonMACE Trial

Researchers

Presenter

  • Kalantar-Zadeh Kamyar

Principal Investigators

  • Schwartz GregoryG

  • Buhr KevinA

  • Ginsberg HenryN

  • Johansson JanO

  • Kulikowski Ewelina

  • Nicholls StephenJ

  • Toth PeterPaul

  • Wong NormanCw

  • Sweeney Michael

  • Ray KausikK

Medical Centers

  • University of California, Davis, Davis, California, United States

  • University of Colorado Denver School of Medicine Aurora Colorado United States

  • Statistical Data Analysis Center University of Wisconsin-Madison Madison Wisconsin United States

  • Columbia University, New York, New York, United States

  • FibroGen Inc., San Francisco, California, United States

  • Resverlogix Calgary Alberta Canada

  • Monash Cardiovascular Research Centre Monash University Melbourne Victoria Australia

  • John Hopkins University, Baltimore, Maryland, United States

  • Imperial Centre for Cardiovascular Disease Prevention Imperial College London London United Kingdom

Locations

  • United States

  • Canada

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Congestive heart failure

  • Acute Coronary Syndromes

  • Diabetes

  • Stroke

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved